Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $7,803,986.74 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Jude Onyia sold 59,819 shares of the firm's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total value of $7,803,986.74. Following the completion of the sale, the insider directly owned 18,289 shares in the company, valued at approximately $2,385,982.94. The trade was a 76.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jude Onyia also recently made the following trade(s):

• On Wednesday, July 2nd, Jude Onyia sold 20,362 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $130.13, for a total value of $2,649,707.06.

Neurocrine Biosciences Trading Down 1.1%

Shares of NBIX stock traded down $1.46 during mid-day trading on Friday, reaching $133.46. The stock had a trading volume of 724,778 shares, compared to its average volume of 1,143,853. The stock's 50-day moving average price is $124.19 and its two-hundred day moving average price is $121.63. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $157.98. The firm has a market capitalization of $13.21 billion, a PE ratio of 45.24, a price-to-earnings-growth ratio of 1.37 and a beta of 0.24.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The business had revenue of $572.60 million for the quarter, compared to analysts' expectations of $587.06 million. During the same period last year, the firm posted $1.20 earnings per share. Neurocrine Biosciences's quarterly revenue was up 11.1% on a year-over-year basis. On average, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Hedge Funds Weigh In On Neurocrine Biosciences

Hedge funds have recently made changes to their positions in the business. Avantax Advisory Services Inc. increased its stake in shares of Neurocrine Biosciences by 11.4% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,895 shares of the company's stock valued at $395,000 after buying an additional 297 shares during the period. Corient Private Wealth LLC increased its position in shares of Neurocrine Biosciences by 64.0% during the fourth quarter. Corient Private Wealth LLC now owns 7,927 shares of the company's stock valued at $1,082,000 after buying an additional 3,094 shares during the period. B. Metzler seel. Sohn & Co. AG increased its position in shares of Neurocrine Biosciences by 5.1% during the fourth quarter. B. Metzler seel. Sohn & Co. AG now owns 5,044 shares of the company's stock valued at $689,000 after buying an additional 245 shares during the period. Golden State Wealth Management LLC increased its position in shares of Neurocrine Biosciences by 116.9% during the first quarter. Golden State Wealth Management LLC now owns 397 shares of the company's stock valued at $44,000 after buying an additional 214 shares during the period. Finally, Fifth Third Bancorp increased its position in shares of Neurocrine Biosciences by 31.7% during the first quarter. Fifth Third Bancorp now owns 1,056 shares of the company's stock valued at $117,000 after buying an additional 254 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Neurocrine Biosciences in a research report on Thursday. They set a "buy" rating and a $182.00 price objective on the stock. Royal Bank Of Canada restated an "outperform" rating and set a $145.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, June 2nd. Canaccord Genuity Group raised their price objective on Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Guggenheim raised their price objective on Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, Wall Street Zen cut Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. Three analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.